Lycopene prevents lipid accumulation in hepatocytes by stimulating PPARα and improving mitochondrial function

Jia, Weiping; Geng, Tonghui; Zou, Qianhui; Yang, Ningru; Zhao, Wenting; Li, Yitong; Tan, Xiao Di; Tian, Yuan; Liu, Xuebo; Liu, Zhigang

doi:10.1016/j.jff.2020.103857

Cited by 24 publications

(14 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, dietary phytochemicals or phytochemical-rich plant extracts have been increasingly appreciated as effective agents for alleviation of fatty liver disease [3,4]. Among the phytochemical candidates, carotenoids, owing to their generally hydrophobic nature, have exhibited promising efficacy in preclinical models of NAFLD and NASH [5].…”

Section: Introductionmentioning

confidence: 99%

“…Among the phytochemical candidates, carotenoids, owing to their generally hydrophobic nature, have exhibited promising efficacy in preclinical models of NAFLD and NASH [5]. For instance, lycopene was reported to attenuate lipid accumulation in human liver cell lines and prevent the development of high-fat-diet (HFD) induced NASH in rodents [3].…”

Section: Introductionmentioning

confidence: 99%

“…This in turn would further contribute to progression of the disease due to impaired mitochondrial fatty acid metabolism [10]. It has been reported that improving mitochondrial function could help to prevent hepatic lipid accumulation [3]. Acetyl-CoA carboxylase (ACC), the rate-limiting enzyme of fatty acid biosynthesis, plays a critical role in hepatic lipid metabolism.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Lipid-Lowering Bioactivity of Microalga Nitzschia laevis Extract Containing Fucoxanthin in Murine Model and Carcinomic Hepatocytes

et al. 2021

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD), characterized by hepatic steatosis, is one of the most common liver diseases worldwide. So far, no definitive medical treatment has been established to treat NAFLD except for lifestyle medication. Nitzschia laevis extract (NLE), a microalgal extract rich in fucoxanthin, has been previously demonstrated to reduce bodyweight in high-fat-diet (HFD) C57BL/6J mice, indicating potential for prevention of NAFLD. In the present study, we investigated the lipid-lowering effects of NLE in HFD-induced steatosis murine model and palmitate-treated HepG2 cells. The results showed that NLE significantly lowered inguinal fat and attenuated hepatic steatosis in C57BL/6J mice. Especially, NLE significantly prevented lipid accumulation in HepG2 cells. This was probably due to its capability to enhance hepatic mitochondrial function as evidenced by the increased oxygen consumption rate (OCR) and mitochondrial membrane potential (MMP), and repress fatty acid synthesis through phosphorylation of acetyl-CoA carboxylase (ACC). Moreover, fucoxanthin was identified to be responsible for the lipid-lowering effect of NLE. Taken together, NLE or other microalgal fucoxanthin-rich products are promising natural products that may help prevent against NAFLD.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Lipid-Lowering Bioactivity of Microalga Nitzschia laevis Extract Containing Fucoxanthin in Murine Model and Carcinomic Hepatocytes

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In mice given a Western diet, LP treatment significantly decreased fat accumulation by increasing PPAR- α activity. In order to demonstrate its antioxidant properties, LP also boosted the production of mitochondrial complexes, HO-1, and NQO1 185 .…”

Section: Terpenoidsmentioning

confidence: 99%

Bioprotective Role of Phytocompounds Against the Pathogenesis of Non-alcoholic Fatty Liver Disease to Non-alcoholic Steatohepatitis: Unravelling Underlying Molecular Mechanisms

Banerjee,

Sarkar,

Ali

et al. 2024

Planta Med

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD), with a global prevalence of 25%, continues to escalate, creating noteworthy concerns towards the global health burden. NAFLD causes triglycerides and free fatty acids to build-up in the liver. The excessive fat build-up causes inflammation and damages the healthy hepatocytes leading to non-alcoholic steatohepatitis (NASH). Dietary habits, obesity, insulin resistance, type 2 diabetes, and dyslipidemia influence NAFLD progression. The disease burden is complicated due to the paucity of therapeutic interventions. Obeticholic acid is the only approved therapeutic agent for NAFLD. With more scientific enterprise being directed towards understanding of underlying mechanisms of NAFLD, novel targets like lipid synthase, farnesoid X receptor signalling, peroxisome proliferator-activated receptors associated with inflammatory signalling and hepatocellular injury have played a crucial role in progression of NAFLD to NASH. Phytocompounds have shown promising results in modulating hepatic lipid metabolism and de novo lipogenesis suggesting their possible role in managing NAFLD. This review discusses the ameliorative role of different classes of phytochemicals with molecular mechanisms in different cell lines and established animal models. These compounds may lead to the development of novel therapeutic strategies for NAFLD progression to NASH. This review also deliberates on phytomolecules undergoing clinical trials for effective management of NAFLD.

show abstract

“…to reduce the secretion of inflammatory cytokines by adipocytes; Therefore, reducing the risk of diseases associated with dyslipidemia and obesity [32]. In mice fed a high-fat, high-fructose (HFFD) diet, it was found that lycopene therapy reduced weight gain and liver weight [33].…”

Section: Antioxidant Activity Of Lycopenementioning

confidence: 99%

Risk reduction and prevention of cardiovascular diseases: biological mechanisms of lycopene

Rejali¹,

Ozumerzifon²,

Nayeri³

et al. 2022

BCHD

View full text Add to dashboard Cite

Background and aims: The conservational effects of dietary interventions as advantageous instruments in the primary and secondary prevention of cardiovascular disease (CVD) have gotten more attention in recent years. Numerous nutritional epidemiological studies have highlighted the ability of diets to decrease costly care and treatments as well as adverse side effects from standard treatments. Lycopene is a non-pro-vitamin A carotenoid that is present in tomatoes, processed tomato products, and different fruits like watermelon, autumn olive, gac, pink grapefruit, pink guava, papaya, sea buckthorn, and wolfberry. As one of the most powerful antioxidants among dietary tetraterpenoids, lycopene can also assist in lowering the risk of early death and extending life in patients with heart disease. By reducing the destructive effects of free radicals along with total and “bad” LDL cholesterol levels while increasing “good” HDL cholesterol, lycopene holds the power to reduce the risk factors of heart disease. Several studies have investigated a reduction of oxidized-LDL (oxLDL) cholesterol levels following lycopene consumption which supports these claims and suggests the conceivable function of lycopene in the blockage of oxidative stress-associated CVD. A negative correlation between serum lycopene concentration and mortality of people with metabolic syndrome was found. Over 10 years, researchers observed a 39% decreased chance of premature death in individuals with the metabolic disease who had the highest blood concentrations of lycopene. Lycopene’s protective impacts are especially beneficial in those with low blood antioxidant levels or high levels of oxidative stress. This includes older adults, smokers, and diabetic individuals or other vascular disorders. Lycopene intake has been thought to reduce the risk of obesity, insulin resistance, and diabetes mellitus.Lycopene acts as an antihypertensive agent by impeding the angiotensin-converting enzyme and improving the production of nitric oxide (NO) in the endothelium. The purpose of this review is to summarize the possible mechanisms of lycopene in the prevention of CVD. Keywords: Lycopene, Risk factors of heart disease, Antioxidants, Carotenoids, Cardio-metabolic, Insulin resistance

show abstract

Lycopene prevents lipid accumulation in hepatocytes by stimulating PPARα and improving mitochondrial function

Cited by 24 publications

References 44 publications

Lipid-Lowering Bioactivity of Microalga Nitzschia laevis Extract Containing Fucoxanthin in Murine Model and Carcinomic Hepatocytes

Lipid-Lowering Bioactivity of Microalga Nitzschia laevis Extract Containing Fucoxanthin in Murine Model and Carcinomic Hepatocytes

Bioprotective Role of Phytocompounds Against the Pathogenesis of Non-alcoholic Fatty Liver Disease to Non-alcoholic Steatohepatitis: Unravelling Underlying Molecular Mechanisms

Risk reduction and prevention of cardiovascular diseases: biological mechanisms of lycopene

Contact Info

Product

Resources

About